The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible ...

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did ...

The Centers for Medicare & Medicaid Services (CMS) has sought public comments as the agency plans to list up to 15 additional ...

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in ...

President Trump’s executive order to lower drug prices through cross-agency action left pharma leaders scrambling to make ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

CMS proposed several changes for the third round of Medicare drug price negotiations, including the potential inclusion of some drugs under Medicare Part B, in a draft guidance published May 12. The ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

President Trump signed an executive order aimed at making pharmaceutical companies charge their US customers no more than the ...

CMS said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year. For the first time, the list would include drugs ...